Form 4 for BCRX BIOCRYST PHARMACEUTICALS INC
Accepted 2021-09-17 00:00:00 ET · period of report 2021-09-15 · accession 0001127602-21-025496 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-09-17 | 2021-09-15 | BCRX | ABERCROMBIE GEORGE B | Dir | S - Sale+OE | $15.06 | -5,000 | 0 | -100% | -$75.3K |
| D | 2021-09-17 | 2021-09-15 | BCRX | ABERCROMBIE GEORGE B | Dir | M - OptEx | $2.63 | +5,000 | 5,000 | New | +$13.2K |
| D | 2021-09-17 | 2021-09-15 | BCRX | ABERCROMBIE GEORGE B | Dir | M - OptEx | $0.00 | -5,000 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-09-15 | S | D | 5,000 | $15.06 | 0 | D | — | — | (F1) This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. (F2) The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $14.90 to $15.40. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2021-09-15 | M | A | 5,000 | $2.63 | 5,000 | D | — | — | (F1) This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. |
| 3 | Derivative | Non-Qualified Stock Option | 2021-09-15 | M | D | 5,000 | $0.00 | 0 | D | $2.63 · — to 2021-10-10 | 5,000 Common Stock | (F1) This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. (F3) The option vested 1/8 per month for a period of 8 months, beginning on October 10, 2011. |